Kent W. Mouw

Also affiliated with Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Dana-Farber Brigham Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Genomic Landscape of Primary and Recurrent Anal Squamous Cell Carcinomas in Relation to HPV Integration, Copy-Number Variation, and DNA Damage Response Genes

(2023)10.1158/1541-7786.c.6545376.v1

Top 100%

0DataRank

Top 100%0 citations

David R. Lorenz, Kent W. Mouw, Alan D. D’Andrea, Dana Gabuzda, Jordan Aldersley

Papers

Driven by 23 papers — median percentile 0. Top paper: “Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial”.

Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial

Nature Medicine(2023)10.1038/s41591-023-02568-1

N/A

5.2DataRank · unranked

135 citations

Siamak Daneshmand, Sudeh Izadmehr, Edgar Gonzalez‐Kozlova, Kevin Chan, Sara Lewis +35 more

Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors

Cancer Cell(2022)10.1016/j.ccell.2022.08.022

N/A

0.717DataRank · unranked

118 citations

Elio Adib, Sarah Abou Alaiwi, Talal El Zarif, Stefan Groha, Elie W. Akl +27 more

Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology

Nature Cancer(2021)10.1038/s43018-021-00243-3

N/A

0.574DataRank · unranked

45 citations

Nathanael D. Moore, Nicholas Moore, Eric Kofman, Saud H. AlDubayan, Alexander T. M. Cheung +14 more

RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics

Journal of Clinical Investigation(2021)10.1172/jci147849

N/A

0.533DataRank · unranked

34 citations

Amruta S. Samant, Amin H. Nassar, Jonathan So, Elizabeth P. Garcia, Catherine R. Curran +13 more

A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5034

N/A

0.461DataRank · unranked

8 citations

Wanling Xie, Edmund Folefac, Daniel Lee, Mamta Parikh, David J. Einstein +12 more

Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates

JCO Precision Oncology(2024)10.1200/po.23.00362

N/A

0.262DataRank · unranked

3 citations

Henkel Valentine, David Liu, Michael J. Slifker, Costas D. Lallas, Edouard J. Trabulsi +24 more

Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4562

N/A

0.104DataRank · unranked

1 citations

Woonyoung Choi, Susan Halabi, Bin Luo, Hikmat Al‐Ahmadie, Jonathan E. Rosenberg +12 more

Association of DNA damage repair (DDR) mutations (mts) and clinical outcomes in CALGB 90601 (Alliance).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4521

N/A

0DataRank · unranked

0 citations

Susan Halabi, Bin Luo, Jonathan E. Rosenberg, Woonyoung Choi, Hikmat Al‐Ahmadie +12 more

Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0792

N/A

0DataRank · unranked

17 citations

Yuzhen Zhou, Keisuke Otani, Michael Drumm, Yukako Otani, Shulin Wu +17 more

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma

Scientific Reports(2023)10.1038/s41598-023-47946-4

N/A

0DataRank · unranked

9 citations

Haohui Duan, Viktória Tisza, Pranshu Sahgal, Sabine Topka, Gregory T. Klus +17 more

A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4607

N/A

0DataRank · unranked

3 citations

Nicholas I. Simon, Scot A. Niglio, Lisa Ley, Lisa M. Cordes, Rouf Banday +15 more

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.02.07.527498

N/A

0DataRank · unranked

2 citations

Haohui Duan, Viktória Tisza, Pranshu Sahgal, Sabine Topka, Gregory T. Klus +17 more

Data from Genomic Landscape of Primary and Recurrent Anal Squamous Cell Carcinomas in Relation to HPV Integration, Copy-Number Variation, and DNA Damage Response Genes

(2023)10.1158/1541-7786.c.6545376.v1

Top 100%

0DataRank

Top 100%0 citations

David R. Lorenz, Kent W. Mouw, Alan D. D’Andrea, Dana Gabuzda, Jordan Aldersley

Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008436

N/A

0DataRank · unranked

13 citations

Harshabad Singh, Lestat R. Ali, Nora Horick, S. Jennifer Wang, Megan T. Hoffman +33 more

Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712

European Urology Oncology(2024)10.1016/j.euo.2024.03.015

N/A

0DataRank · unranked

2 citations

Sophia C. Kamran, Amol C. Shetty, Philip Sutera, Yang Song, Soha Bazyar +29 more

EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair

Oncogene(2020)10.1038/s41388-020-1332-2

N/A

0DataRank · unranked

57 citations

Matthew Z. Madden, Dongkyoo Park, Elizabeth V. Minten, Priya Kapoor-Vazirani, Erica Werner +17 more

APOBEC3A-Induced DNA Damage Drives Polymerase θ Dependency and Synthetic Lethality in Cancer

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.10.21.682588

N/A

0DataRank · unranked

1 citations

Weisi Liu, Paul Yoo, Alina Sami, Michal T. Boniecki, Madhura Deshpande +14 more

Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 Pandemic

JAMA Oncology(2020)10.1001/jamaoncol.2020.3545

N/A

0DataRank · unranked

28 citations

Brandon A. Mahal, Melaku A. Arega, Anthony V. D’Amico, Kent W. Mouw, Paul L. Nguyen +2 more

A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps5597

N/A

0DataRank · unranked

3 citations

Wanling Xie, Mamta Parikh, Daniel Lee, Elizabeth R. Kessler, David J. Einstein +8 more

Clinical interpretation of integrative molecular profiles to guide precision cancer medicine

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.09.22.308833

N/A

0DataRank · unranked

0 citations

Nathaniel D Moore, Nicholas Moore, Eric Kofman, Saud H. AlDubayan, Alexander T. M. Cheung +14 more

A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.tps252

N/A

0DataRank · unranked

0 citations

Wanling Xie, Mamta Parikh, Daniel Lee, Elizabeth R. Kessler, David J. Einstein +8 more

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

npj Precision Oncology(2022)10.1038/s41698-022-00291-7

N/A

0DataRank · unranked

27 citations

Raie Bekele, Zsofia Sztupinszki, Timothy Hanlon, Shahrzad Rafiei, Zoltán Szállási +3 more

Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy

The Prostate(2022)10.1002/pros.24362

N/A

0DataRank · unranked

4 citations

Vedang Murthy, Kent W. Mouw, Anthony V. D’Amico, Paul L. Nguyen, Jonathan E. Leeman +2 more

Kent W. Mouw

Indexed papers

Top data-sharing exemplar

Papers